Background: For locally unresectable recurrent squamous cellcarcinoma of the head and neck, we investigated two salvage chemotherapy regimens as second-line chemotherapy. In our preliminary study, we observed that both regimens were active. In the present studywe analyzed the prognosis of these patients. Methods:Twenty-sixpatients with recurrent advanced head and neck cancer, were treated with one of two new regimens as second-line chemotherapy. The PEM regimen consisted of cisplatin 60 mg/m 2 on day 1, etoposide 40 mg/m 2 on days 1, 2 and 3 and mitomycin-C 7 mg/m 2 on day 1. The long CF regimen consisted of cisplatin 8 mg/m 2 on days 1-5, 8-12, 15-19 and 22-26 and 5-fluorouracil 300 mg/m 2 as a 24 h infusion or oral administration of tegaful-uracil (UFT-E) 400 mg/m 2 on days 1-28. Survival curves were calculated using the Kaplan-Meier method and compared by the log rank test. Results: Of 24 patients evaluable for response, three complete responses (CR)andsevenpartial responses (PR) were achieved, with an overall response rateof 42%. Myelosuppression was the major side effect. One year survival was 100% for CR, 0% for PR and 20% for minor response (MR). All patients who failed to achieve a CR died within 12 months, exceptone patientwith MR. Conclusion: Our data suggest that with these salvage regimens survival benefit was demonstrated only in CR patients.
INTRODUCTION
In patients who have advanced squamous cell carcinoma of the head and neck with large nodal involvement, the expected 5-year survival is as low as 1-2% (1) . Chemotherapy has been added to the standard regimen of surgery and radiotherapy in attempts to improve the outcome in such patients. A number of cytotoxic agents have been identified as active in the treatment of this Received May 13, 1999 ; accepted June 12, 1999 For reprints and all correspondence: Naoyuki Kohno, Department of Otorhinolaryngology, National Defense Medical College, 3-2 Namiki, Tokorosawa, Saitama, Japan Abbreviations: CR, complete response; PR, partial response; MR, minor response; SD, stable disease; PO, progressive disease; RR, response rate; PS, performance status; COOP, cisplatin; 5-FU, 5-fluorouracil; MTX, methotrexate; BLM, bleomycin; MMC, mitomycin-C; OFT-E, tegaful-uracil; BUN, blood urea nitrogen; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamic pyruvate transaminase; ECOG, Eastern Cooperative Oncology Group; MTS, multicellular tumor spheroids disease. Currently, cisplatin (CDDP)-based combination regimens such as CDDP plus 5-fluorouracil (5-FU) or CDDP plus methotrexate (MTX) plus bleomycin (BLM) are widely used. These regimens produced a complete response (CR) rate of 30-60% and overall response rates (RR) of 80-100% (2-5). However, in previously treated patients, the overall and complete response rates have been disappointingly low (6) (7) (8) . Patients who have already been treated with CDDP-based regimens and have shown recurrence or are refractory to these regimens ultimately die of their disease.
Based on this background we developed two new regimens which we designated PEM and L-CF. In our preliminary analysis we observed that these regimens were active as salvage treatments (9) . In the present study we analyzed the impact of these salvage regimens on survival.
MATERIALS AND METHODS
Between The chemotherapy regimens were as follows. The PEM regimenconsists of CDDP60 mg/m-' in 500 ml of normalsaline as a 2 h infusion on day 1, etoposide 40 mg/m-in 200 ml of normal saline as a 1 h infusion on days 1, 2 and 3 and mitomycin-C (MMC) 7 mg/m 2 i.v. boluson day 1. Patientswere hydrated· with 5% glucose with a half normal saline to ensure a urine output of more than 100 ml/h and premedicated with granisetron 40 mg/kg30minbeforethe startof cisplatin infusion. The long CF (L-CF) regimen consisted of CDDP 8 mg/m 2 in 500 m1 of normal saline as a 2 h infusion on days 1-5, 8-12, 15-19 and 22-26 and 5-FU 300 mg/m-' in 1000 rnl of normal saline as a 24 h infusion or oral administration of tegaful-uracil (UFT-E) 400 mg/m-' on days 1-28. No hydration wasrequiredfor administration of low doses of cisplatin. Patients were assigned randomlyto either PEM or L-CF regimens. Both regimens were repeated at 3--4-week intervals as hematological toxicities permitted. Both regimens were given on an in-patient basis.The treatment was discontinued when a patient was found to have progressive disease (PD) or the toxicity exceeded the benefits of continueddrug administration.
Response to treatment was assessed as the decrease in the total tumor area measureddirectly with calipers or throughradiological features. Complete response (CR) was defined as the disappearance of all measurable and assessable disease for a minimumdurationof 4 weeks. Partial response (PR)was defined as a~50% reduction in the sum of the products of the perpendicular diameters of all measurable lesions without an increasein the sizeof any lesionor the appearance of new lesions for at least 4 weeks. Minor response (MR) was defined as a decreaseof 25-50%. Stabledisease (SD) wasdefinedas a change in the sum of the products of the perpendicular diameters of all measured lesions of <25%. PD was defined as an increase of >25% in the sum of the products of the perpendicular diameters of all measuredlesions from the point of maximumresponseor the appearances of new lesions. All patients not meeting the criteriafor CR or PR wereclassified as non-responders. Duration of response wasmeasured fromthedateof first documentation of responseto the date of disease progression. Survival curves were calculatedusingthe Kaplan-Meiermethod (10)andcomparedby the log rank test (11) .
Post-treatment follow-up differed according to the responseto treatment and site of the primary tumor. Patients with CR underwenta physicalexamination everymonthduringthe 2 years after the end of treatment and every 2 months after the second year. Patients with PR, MR and SD were examinedmonthly. Adverse reactions are listed in Table 5 . Because of the small number of patientsin eachgroup,combinedsideeffectsarelisted. The most frequently observedtoxicities werenauseaor vomiting. These side effects occurred in spite of premedication with granisetron.Myelosuppression was a majorside effectand severe thrombocytopeniaoccurredin threepatients. These three patients plus another two patients discontinued further chemotherapy owing to side effects. Mucositis was observed in previously irradiated patients.
Maximum response of -----------------
Twenty-one patients have died of disease. One year survival was 100% for CR, 0% for PR, 20% for MR and 0% for SD and PD, respectively. One of threeCR patientsdied in the second year and others are alive with local recurrence 36+ months and disease-free 60+ months (Fig. 1) . Survival curves showed a significant difference in favor of the complete responders vs non-complete responders (P < 0.05).
DISCUSSION
This study demonstrates that patients with inoperable squamous cell carcinoma of the head and neck who had previously been subjected to cisplatin-containing chemotherapy respond to second-line cisplatin-containing regimens;however, survivaladvantages were seen only in complete responders.
It has repeatedlybeen reportedthat in the treatmentof head and neck carcinoma survivaladvantagewas seenonly in patients with responses (12, 13) . Our studyextendedthisobservationto salvage chemotherapy.
The PEM regimen was conceived because topoisomerase II inhibitors such as etoposide were reported to be synergisticwith CDDP (14) . MMC was added because of its reported efficacy against hypoxic cells and of synergistic interaction with CDDP (15) .Wehave previously shownthat with the use of multicellular tumor spheroids (MTS), poor drug penetration into the core is a major hindrance governing the cell kill effect at a three-dimensional tumor mass level. Prior exposure to CDDP was effective in enhancing penetration of drugs known to be poor penetrants, such as doxorubicin (16) . Indeed, our initial clinical trial of the PEM regimen showed a high response rate in previously untreated patients with head and neck cancer (17) .
The L-CF regimen was conceived as a means of dose intensification. Dose intensification of cytotoxic drugs has been positively correlated with increased clinical response (18) . We questioned whetherthe use of low-doseprolonged5-FU infusion and low doses of daily CDDP might permit the administration of increasedamountsof drugsperunittimeperiod.Weobservedthat the L-CF regimen allowed the administration of 160 mg/m 2/month of CDDPand 8400mg/m 2/month of 5-FU without major dose-limiting toxicities, doses much intensified as compared with conventional CDDP plus 5-FU regimens. In addition, our work with MTS demonstrated that there was a steep dose-responsecurve in favor of a prolonged5-FU exposure time (19) infusion. Because a tegaful-uracil capsule contains 100 mg of Nl_(2' -tetrahydrofuryl)-5-fluorouracil, the calculated tegafuluracil dose was rounded off to the nearest 100 mg.
Weobservedthatboth thePEMandL-CFregimenswereactive in inducing tumor regression. Because of the small number of patients involved in each regimen, we carried out only a combined analysis.
For patients who experienced grade ill toxicity, further chemotherapy was stopped. However, these patients showed an adverse reaction after the end of scheduledchemotherapy, so all the patients were continuedon the planned regimen. Figure 1 . Actuarialsurvivalfor 24 patientsentered in the study. Survivalcurves were calculated using the Kaplan-Meier method. Significant differences were comparedwith the log rank test.Survivalcurvesshoweda significantdifference in favor of the completeresponders vs partial and non-responders (P < 0.05).
*All patients except two were premedicated with granisetrone. "Iransient increases in serum creatinine.
Several lessons can be learned from the present study. As expected, the response to salvage treatment was low. Nevertheless, responders to the salvage treatment had previously been exposed to CDDP and had responded. Therefore, it is likely that prior exposure to CDDP does not necessarily mean CDDP resistance. CDDP dose intensification may play a role in induction of the second response.
The most important finding of the present study is the increases in survival observed among the CR patients in a salvage setting. Unfortunately, the CR rate was so low that the routine use of these two regimens does not appear to have added significantly to the overall survival of the study population. Since, however, the majority of courses were well tolerated and toxicity was limited, it is tempting, in order to increase the CR rate, to carry out further escalation of dose intensification by addition of hematopoietic growth factors and/or stem cell transplantation.
